TREADWELL Trademark

Trademark Overview

On Wednesday, April 8, 2020, a trademark application was filed for TREADWELL with the United States Patent and Trademark Office. The USPTO has given the TREADWELL trademark a serial number of 88864454. The federal status of this trademark filing is SUSPENSION LETTER - MAILED as of Tuesday, May 13, 2025. This trademark is owned by Treadwell Therapeutics Canada Inc.. The TREADWELL trademark is filed in the Pharmaceutical Products and Computer & Software Services & Scientific Services categories with the following description:

pharmaceuticals for the treatment of cancer and auto-immune diseases; therapeutic products being small molecule, biologics, and cell therapies, namely, pharmaceutical preparations for the treatment and prevention of cancer and autoimmune diseases

research and development in the field of pharmaceuticals and product research and development in the field of therapeutic products
treadwell

General Information

Serial Number88864454
Word MarkTREADWELL
Filing DateWednesday, April 8, 2020
Status653 - SUSPENSION LETTER - MAILED
Status DateTuesday, May 13, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements

Goods and Servicespharmaceuticals for the treatment of cancer and auto-immune diseases; therapeutic products being small molecule, biologics, and cell therapies, namely, pharmaceutical preparations for the treatment and prevention of cancer and autoimmune diseases
Goods and Servicesresearch and development in the field of pharmaceuticals and product research and development in the field of therapeutic products

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, April 16, 2020
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE
International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateThursday, April 16, 2020
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameTreadwell Therapeutics Canada Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressToronto, Ontario M5G2M9
CA

Trademark Events

Event DateEvent Description
Saturday, April 11, 2020NEW APPLICATION ENTERED
Thursday, June 25, 2020ASSIGNED TO EXAMINER
Thursday, April 16, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Saturday, June 27, 2020NON-FINAL ACTION WRITTEN
Saturday, June 27, 2020NON-FINAL ACTION E-MAILED
Saturday, June 27, 2020NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, November 2, 2020TEAS CHANGE OF OWNER ADDRESS RECEIVED
Monday, November 2, 2020TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Monday, November 2, 2020ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Monday, November 2, 2020APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Monday, November 2, 2020TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, December 23, 2020TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, December 22, 2020TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, December 22, 2020CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, September 1, 2021REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Thursday, November 4, 2021TEAS CHANGE OF OWNER ADDRESS RECEIVED
Thursday, November 4, 2021TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, January 12, 2021SUSPENSION LETTER WRITTEN
Tuesday, January 12, 2021LETTER OF SUSPENSION E-MAILED
Tuesday, January 12, 2021NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Thursday, November 4, 2021APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Tuesday, March 1, 2022REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Friday, October 14, 2022SUSPENSION INQUIRY WRITTEN
Friday, October 14, 2022INQUIRY TO SUSPENSION E-MAILED
Friday, October 14, 2022NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Tuesday, April 11, 2023TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Tuesday, August 22, 2023ASSIGNED TO LIE
Wednesday, August 23, 2023SUSPENSION LETTER WRITTEN
Wednesday, August 23, 2023LETTER OF SUSPENSION E-MAILED
Wednesday, August 23, 2023NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Wednesday, February 21, 2024SUSPENSION INQUIRY WRITTEN
Friday, September 2, 2022SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Tuesday, August 22, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, August 22, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, February 21, 2024INQUIRY TO SUSPENSION E-MAILED
Wednesday, February 21, 2024NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Thursday, August 15, 2024NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Friday, May 17, 2024TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Monday, May 20, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, May 20, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, August 15, 2024LETTER OF SUSPENSION E-MAILED
Thursday, February 13, 2025INQUIRY TO SUSPENSION E-MAILED
Thursday, February 13, 2025NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Thursday, August 15, 2024SUSPENSION LETTER WRITTEN
Monday, May 12, 2025TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Tuesday, May 13, 2025CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, May 13, 2025TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, May 13, 2025NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Tuesday, May 13, 2025SUSPENSION LETTER WRITTEN
Tuesday, May 13, 2025LETTER OF SUSPENSION E-MAILED
Thursday, February 13, 2025SUSPENSION INQUIRY WRITTEN

Related Keywords

treadwell products development research pharmaceuticals diseases therapeutic treatment cancer field prevention